Welcome

Dear  Subscriber,

Welcome to the latest edition of ‘BrainMatters News”, brought to you by Sanofi.

 

In this edition we invite you to complete a new CPD educational module, created independently by DoctorCPD.ie. This module reviews the diagnosis, classification and treatment of bipolar disorder in clinical practice.

 

Our team has also reviewed the latest research on bipolar disorder from a range of clinical psychiatric journals and selected the following two articles we think you may find interesting:

  • Patterns and predictors of conversion to bipolar disorder in 91,587 individuals diagnosed with unipolar depression
  • Is recurrence in major depressive disorder related to bipolarity and mixed features?

We hope you find this information of use and we look forward to your feedback.

Sincerely,

The 'BrainMatters News' Team

E-CME: Bipolar Disorder - Diagnosis and Treatment (2 CPD Hours)
 

As part of Sanofi’s commitment to support psychiatrists in Ireland we are delighted to inform you of the availability of a new independently created CPD module titled “Bipolar Disorder — Diagnosis & Treatment”.

 

This new online educational module was created independently by DoctorCPD and its goal is to review the diagnosis, classification and treatment of bipolar disorder in clinical practice specifically with a focus on the presentation of bipolar II disorder.  (Please note that this website contains promotional online adverts from Sanofi.)

 

 

Click here to access this module online

 

Please note: By clicking on the link above you will be directed to www.doctorcpd.ie This website is an external website which is neither owned nor controlled by Sanofi-Aventis Ireland Limited. Sanofi-Aventis Ireland Limited accepts no responsibility or liability for the content, products or services of the linked site. Please contact the external website directly if you have questions regarding its accuracy, legality or content.  To access this content you will require a username and password for www.doctorcpd.ie.

 

This module was independently created and is owned by DoctorCPD and the editorial content resides with the author. The views and opinions of the author/contributors are not necessarily those of Sanofi. 

 

Patterns and predictors of conversion to bipolar disorder in 91,587 individuals diagnosed with unipolar depression
 

Musliner KL, Ostergaard SD.

 

Acta Psychiatr Scand 2018 Mar 2. doi 10.1111/acps.12869

 

Depression is one of the most common and most prevalent initial manifestations in the clinical course of bipolar disorder (BD). Unipolar depression (UD), in addition, presents therapeutic aspects that are clearly different from those of the depressive syndromes...

 

Read more
Is recurrence in major depressive disorder related to bipolarity and mixed features?
 

Results from the BRIDGE-II-Mix Study

Mazzarini L. Kotzalidis GD, Piacentino D, Rizzato S, Angst J, Azorin JM, Bodwen CL, Mosolov V, Young AH, Vieta E, Girardi P, Perugi G, BRIDGE-II-Mix Study Group.

J Affect Disord 2018 ; 229: 164-170. doi: 10.1016/jad.2017.12.062.  

It is sometimes difficult to make the differential diagnosis between bipolar disorder and major depressive disorder. This aspect is critical with respect to specific treatment. Current classification systems define both clinical entities....

 

Read more




SAFETY WARNING FOR WOMEN AND GIRLS: Valproate should not be prescribed to female children, female adolescents, women of childbearing potential or pregnant women unless other treatments are ineffective or not tolerated.1,2




 

SAIE.VPA.18.04.0116Date of Preparation: April 2018

 

You are receiving this email because you have agreed to receive information from Sanofi. If you no longer wish to receive emails from the BrainMatters News' series please click on the unsubscribe link.
Please note this email is intended for health care professionals only.

 

References:

1. Epilim Chrono (200 mg, 300 mg, 500 mg) Summary of Product Characteristics. 
2. Epilim Chronosphere (100 mg, 250 mg, 500 mg) Summary of Product Characteristics.